Purpose Because both t (8; 21) and inv (16) disrupt core binding factor (CBF) in acute
myeloid leukemia (AML) and confer relatively favorable prognoses, these cytogenetic …

Core binding factor (CBF) acute myeloid leukemia (AML) is cytogenetically defined by the
presence of t (8; 21)(q22; q22) or inv (16)(p13q22)/t (16; 16)(p13; q22), which are found in …

Core binding factor (CBF) leukemias, characterized by either inv (16)/t (16; 16) or t (8; 21),
constitute acute myeloid leukemia (AML) subgroups with favorable prognosis. However …

PURPOSE: To prospectively compare cytogenetics and reverse transcriptase–polymerase
chain reaction (RT-PCR) for detection of t (8; 21)(q22; q22) and inv (16)(p13q22)/t (16; …

Core-binding factor acute myeloid leukemia (AML) is cytogenetically defined by the
presence of t (8; 21)(q22; q22) or inv (16)(p13q22)/t (16; 16)(p13; q22), commonly …

Acute myeloid leukemia (AML) with t (8; 21) or inv (16) is commonly referred to as core-
binding factor AML (CBF-AML). The incorporation of high-dose cytarabine for postremission …

Acute myeloid leukaemia (AML) has been proposed to arise from the collaboration between
two classes of mutation, a class I, or proliferative, mutation and a class II, or blocking …

We analyzed 338 adult patients with acute myeloid leukemia (AML) with t (8; 21) and inv
(16) undergoing stem cell transplantation (SCT) who were registered in the Japan Society …

Acute myeloid leukemia (AML) with t (8; 21) or inv (16) have been recognized as unique
entities within AML and are usually reported together as core binding factor AML (CBF …

The inv (16) cytogenetic subtype of acute myeloid leukemia (AML) has a relatively good
prognosis. Many patients achieve complete remission (CR). The prognostic uncertainty of …